导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.48% | 2635/4773 |
| 近一周 | -2.27% | 1635/5462 |
| 近一月 | -4.30% | 2369/5421 |
| 近一季 | -7.32% | 2362/5209 |
| 近半年 | -2.32% | 1857/4920 |
| 近一年 | 1.42% | 2337/4366 |
| 近两年 | 49.01% | 1499/2954 |
| 近三年 | 30.00% | 1054/2253 |
| 成立以来 | 37.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.82% 3428/4961 |
12.82% 2112/5312 |
- - |
- - |
| 2025 | 21.01% 2063/4813 |
-0.98% 2508/3635 |
2.31% 1664/4076 |
18.88% 2234/4524 |
0.49% 1973/4813 |
| 2024 | 17.78% 655/3463 |
2.94% 660/2808 |
-1.16% 961/3014 |
17.71% 1136/3129 |
-1.65% 1783/3463 |
| 2023 | -9.62% 1202/2656 |
4.51% 933/2280 |
-4.13% 1064/2385 |
-3.06% 841/2515 |
-6.94% 1987/2655 |
| 2022 | -20.17% 942/2207 |
-14.47% 950/1919 |
7.03% 543/2016 |
-14.33% 1070/2113 |
1.79% 1141/2208 |
| 2021 | -2.46% 856/1822 |
-2.66% 686/1255 |
4.42% 890/1330 |
-5.61% 831/1466 |
1.67% 840/1822 |
| 2020 | 29.12% 546/1250 |
-10.10% 756/1028 |
13.68% 601/1067 |
11.09% 482/1164 |
13.73% 335/1184 |
| 2019 | 38.18% 313/1092 |
28.47% 309/754 |
-0.46% 266/804 |
0.79% 466/850 |
7.21% 469/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.25% 429/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国寿安保沪深300ETF VS. 长安沪深300非周期A(740101) |